Novavax Rallies 20%+ on Report FDA Might Soon Recommend New COVID Vaccine for JN.1 Variant
$Novavax(NVAX.US$ soared more than 20% Monday on a report that the U.S. Food and Drug Administration is considering recommending a new COVID-19 vaccine for the disease's JN.1 variant – a product that NVAX reportedly specializes in.
Novavax rose 21.2% to close at an 18-month high of $18.22 after Yahoo Finance reported that the FDA might soon recommend a JN.1 variant vaccine. The rally took NVAX to its highest closing price since November 2022.
Rival vaccine maker $Moderna(MRNA.US$ rose 3.7% on the news, while $Pfizer(PFE.US$ gained 2.3%, although Yahoo Finance said those firms rely less on COVID-19 vaccines than Novavax does.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Director of Financial Content
Former top editor at Seeking Alpha, Fidelity.com, TheStreet.com and UPI.
299Followers
304Following
1430Visitors
Follow